Effect of Tissue Sample Type on The Evaluation of PD-L1 (SP142) Expression in Breast Cancer
For optimal PD-L1 assessment in breast cancer, surgical specimens from primary tumors without prior therapy are preferable due to larger evaluable tumor areas. For patients requiring neoadjuvant chemotherapy or with <i>de novo</i> Stage IV disease, multiple biopsies of primary tumors using thick needles before treatment, with attention being paid to sampling tumor margins to account for potential immune-excluded phenotypes, are recommended.
Authors
- Tomonori Tanei (ORCID: https://orcid.org/0000-0003-2183-8681)
- Yoshiaki Sota (ORCID: https://orcid.org/0000-0001-5963-652X)
- Masafumi Shimoda (ORCID: https://orcid.org/0000-0002-2465-0118)
- Nanae Masunaga (ORCID: https://orcid.org/0000-0002-6164-5107)
- Tomohiro Miyake (ORCID: https://orcid.org/0000-0002-9362-9822)
- Kaori Abe (ORCID: https://orcid.org/0009-0000-8849-5711)
- Tetsuhiro Yoshinami (ORCID: https://orcid.org/0009-0000-8747-3641)
- Masami Tsukabe (ORCID: https://orcid.org/0009-0009-3284-0833)
- Kenzo Shimazu (ORCID: https://orcid.org/0000-0002-0837-2357)
- Takeshi Usui (ORCID: https://orcid.org/0009-0009-0510-6756)
Institutions
- Osaka City University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17893
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00